{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["113(10)"],"submitter":["Sasaki R"],"funding":["Juntendo University"],"pubmed_abstract":["Trastuzumab-induced cardiotoxicity interferes with continued treatment in approximately 10% of patients with ErbB2-positive breast cancer, but its mechanism has not been fully elucidated. In this study, we recruited trastuzumab-treated patients with ≥30% reduction in left ventricular ejection fraction (SP) and noncardiotoxic patients (NP). From each of these patients, we established three cases of induced pluripotent stem cell-derived cardiomyocytes (pt-iPSC-CMs). Reduced contraction and relaxation velocities following trastuzumab treatment were more evident in SP pt-iPSC-CMs than NP pt-iPSC-CMs, indicating the cardiotoxicity phenotype could be replicated. Differences in ATP production, reactive oxygen species, and autophagy activity were observed between the two groups. Analysis of transc"],"journal":["Cancer science"],"pagination":["3449-3462"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9530879"],"repository":["biostudies-literature"],"pubmed_title":["Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity."],"pmcid":["PMC9530879"],"pubmed_authors":["Kashiyama T","Eguchi H","Shiga T","Miyazaki S","Sasaki R","Kurebayashi N","Akamatsu W","Saito M","Horimoto Y"],"additional_accession":[]},"is_claimable":false,"name":"Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity.","description":"Trastuzumab-induced cardiotoxicity interferes with continued treatment in approximately 10% of patients with ErbB2-positive breast cancer, but its mechanism has not been fully elucidated. In this study, we recruited trastuzumab-treated patients with ≥30% reduction in left ventricular ejection fraction (SP) and noncardiotoxic patients (NP). From each of these patients, we established three cases of induced pluripotent stem cell-derived cardiomyocytes (pt-iPSC-CMs). Reduced contraction and relaxation velocities following trastuzumab treatment were more evident in SP pt-iPSC-CMs than NP pt-iPSC-CMs, indicating the cardiotoxicity phenotype could be replicated. Differences in ATP production, reactive oxygen species, and autophagy activity were observed between the two groups. Analysis of transc","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-21T16:50:09.373Z","creation":"2025-04-05T11:38:13.366Z"},"accession":"S-EPMC9530879","cross_references":{"pubmed":["35879248"],"doi":["10.1111/cas.15508"]}}